Dose-independent influence of metoprolol on cardiac and motor functions, QoL, and mental status in Chinese patients with CHF

References

• WRITING GROUP MEMBERSLloyd-JonesDAdamsRJAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2010 update: a report from the American Heart AssociationCirculation20101217e46e21520019324
   PubMed Web of Science ®Google Scholar
• YangYNMaYTLiuFIncidence and distributing feature of chronic heart failure in adult population of XinjiangZhonghua Xin Xue Guan Bing Za Zhi2010385460464 Chinese20654109
   PubMedGoogle Scholar
• HuSSKongLZGaoRLEditorial BoardOutline of the report on cardiovascular disease in China, 2010Biomed Environ Sci201225325125622840574
   PubMed Web of Science ®Google Scholar
• BhatiaRSTuJVLeeDSOutcome of heart failure with preserved ejection fraction in a population-based studyN Engl J Med2006355326026916855266
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJI-PRESERVE InvestigatorsIrbesartan in patients with heart failure and preserved ejection fractionN Engl J Med2008359232456246719001508
   PubMed Web of Science ®Google Scholar
• OwanTEHodgeDOHergesRMJacobsenSJRogerVLRedfieldMMTrends in prevalence and outcome of heart failure with preserved ejection fractionN Engl J Med2006355325125916855265
   PubMed Web of Science ®Google Scholar
• Al-GobariMEl KhatibCPillonFGueyffierFβ-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trialsBMC Cardiovasc Disord2013135223848972
   PubMed Web of Science ®Google Scholar
• BristowMRTreatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiologyCirc Res2011109101176119422034480
   PubMed Web of Science ®Google Scholar
• NagatsuMSpinaleFGKoideMBradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunctionCirculation2000101665365910673258
   PubMed Web of Science ®Google Scholar
• BristowMRGilbertEMAbrahamWTCarvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA InvestigatorsCirculation19969411280728168941106
   PubMed Web of Science ®Google Scholar
• BristowMRbeta-adrenergic receptor blockade in chronic heart failureCirculation2000101555856910662755
   PubMed Web of Science ®Google Scholar
• FiuzatMWojdylaDKitzmanDRelationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trialJ Am Coll Cardiol201260320821522560018
   PubMed Web of Science ®Google Scholar
• SimonTMary-KrauseMFunck-BrentanoCLechatPJaillonPBisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)Eur Heart J200324655255912643888
   PubMed Web of Science ®Google Scholar
• PrijicSBuchhornRMechanisms of beta-blockers action in patients with heart failureRev Recent Clin Trials201492586025198736
   PubMedGoogle Scholar
• RoyDTalajicMNattelSAtrial Fibrillation and Congestive Heart Failure InvestigatorsRhythm control versus rate control for atrial fibrillation and heart failureN Engl J Med2008358252667267718565859
   PubMed Web of Science ®Google Scholar
• Montero-Perez-BarqueroMFlatherMRoughtonMInfluence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trialEur J Heart Fail20141691009101525044535
   PubMed Web of Science ®Google Scholar
• FloreaVGRectorTSAnandISCohnJNHeart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trialCirc Heart Fail201697e00312327413037
   PubMed Web of Science ®Google Scholar
• EdelmannFMusial-BrightLGelbrichGCIBIS-ELD Investigators and Project Multicenter Trials in the Competence Network Heart FailureTolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: insights from the CIBIS-ELD trialJACC Heart Fail20164214014926682793
   PubMed Web of Science ®Google Scholar
• TateCW3rdRobertsonADZoltyRQuality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST)J Card Fail200713973273717996821
   PubMed Web of Science ®Google Scholar
• DobreDvan JaarsveldCHDejongsteMJHaaijer RuskampFMRanchorAVThe effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysisPharmacoepidemiol Drug Saf200716215215916555368
   PubMed Web of Science ®Google Scholar
• HjalmarsonAGoldsteinSFagerbergBEffects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study GroupJAMA2000283101295130210714728
   PubMed Web of Science ®Google Scholar
• BoyleSHSamadZBeckerRCDepressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart diseasePsychosom Med201375982283124163385
   PubMed Web of Science ®Google Scholar
• RanchordAMSpertusJABuchananDMGoschKLChanPSInitiation of β-blocker therapy and depression after acute myocardial infarctionAm Heart J2016174374226995368
   PubMed Web of Science ®Google Scholar
• MengYLiuXLiuJChengXA prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patientsInt J Cardiol201722726727127843047
   PubMed Web of Science ®Google Scholar
• LiuXLouXChengXMengYImpact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disordersDrug Des Devel Ther201711305312
   PubMed Web of Science ®Google Scholar
• HuangJZhangRLiuXMengYImpact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disordersCurr Med Res Opin201834114114828532169
   PubMed Web of Science ®Google Scholar
• GorreFVandekerckhoveHBeta-blockers: focus on mechanism of action. Which beta-blocker, when and why?Acta Cardiol201065556557021125979
   PubMed Web of Science ®Google Scholar
• HariaMPloskerGLMarkhamAFelodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertensionDrugs200059114115710718104
   PubMed Web of Science ®Google Scholar
• Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot studyCirculation2000101437838410653828
   PubMed Web of Science ®Google Scholar
• PackerMAntonopoulosGVBerlinJAChittamsJKonstamMAUdelsonJEComparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysisAm Heart J2001141689990711376302
   PubMed Web of Science ®Google Scholar
• BergTβ1-Blockers lower norepinephrine release by inhibiting presynaptic, facilitating β1-adrenoceptors in normotensive and hypertensive ratsFront Neurol201455124795691
   PubMed Web of Science ®Google Scholar
• GreenPAnshelevichMTalrejaALong-term effects of carvedilol or metoprolol on left ventricular function in ischemic and nonischemic cardiomyopathyAm J Cardiol20059591114111615842987
   PubMed Web of Science ®Google Scholar
• MetraMNodariSParrinelloGGiubbiniRMancaCDei CasLMarked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significanceAm Heart J2003145229229912595847
   PubMed Web of Science ®Google Scholar
• WilliamsEMHassanMOFlorasJSSleightPJonesJVAdaptation of hypertensives to treatment with cardioselective and non-selective beta-blockers. Absence of correlation between bradycardia and blood pressure control, and reduction in slope of the QT/RR relationBr Heart J19804454734876108122
   PubMedGoogle Scholar
• FlorasJSHassanMOJonesJVSleightPAmbulatory blood pressure and its variability during randomised double-blind administration of atenolol, metoprolol, pindolol and long acting propranolol in subjects with mild to moderate hypertensionDrugs198325Supplement 21925
   Web of Science ®Google Scholar
• de Figueiredo NetoJAMadyCGrupiCEffects of metoprolol tartrate therapy in patients with heart failureArq Bras Cardiol200687332933517057934
   PubMedGoogle Scholar
• ChaveyWEThe importance of beta blockers in the treatment of heart failureAm Fam Physician2000621124532462 English, Portuguese11130231
   PubMed Web of Science ®Google Scholar
• LiuFChenYFengXTengZYuanYBinJEffects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysisPLoS One201493e9055524599093
   PubMed Web of Science ®Google Scholar
• ChatterjeeSBiondi-ZoccaiGAbbateABenefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysisBMJ2013346f5523325883
   PubMed Web of Science ®Google Scholar
• MetraMNodariSD’AloiaABeta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilolJ Am Coll Cardiol20024071248125812383572
   PubMed Web of Science ®Google Scholar
• ArslanSErolMKGundogduFPrognostic value of 6-minute walk test in stable outpatients with heart failureTex Heart Inst J200734216616917622362
   PubMed Web of Science ®Google Scholar
• McAuleyPMyersJAbellaJFroelicherVEvaluation of a specific activity questionnaire to predict mortality in men referred for exercise testingAm Heart J20061514890.e1897.e1
   PubMed Web of Science ®Google Scholar
• WerdanKEbeltHNudingSADDITIONS Study InvestigatorsIvabradine in combination with metoprolol improves symptoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trialCardiology20161332839026501486
   PubMed Web of Science ®Google Scholar
• PetersDHBenfieldPMetoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathyPharmacoeconomics19946437040010147474
   PubMed Web of Science ®Google Scholar
• WiklundIWaagsteinFSwedbergKHjalmarssonAQuality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trialCardiovasc Drugs Ther19961033613688877080
   PubMed Web of Science ®Google Scholar
• WaagsteinFBristowMRSwedbergKBeneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study GroupLancet19933428885144114467902479
   PubMed Web of Science ®Google Scholar
• RiedLDMcFarlandBHJohnsonREBrodyKKBeta-blockers and depression: the more the murkier?Ann Pharmacother19983266997089640490
   PubMed Web of Science ®Google Scholar
• HayesPESchulzSCBeta-blockers in anxiety disordersJ Affect Disord19871321191302890677
   PubMed Web of Science ®Google Scholar
• MacMahonKMLipGYPsychological factors in heart failure: a review of the literatureArch Intern Med2002162550951611871918
   PubMed Web of Science ®Google Scholar
• RutledgeTReisVALinkeSEGreenbergBHMillsPJDepression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomesJ Am Coll Cardiol20064881527153717045884
   PubMed Web of Science ®Google Scholar
• WallePOWestergrenGDimenäsEOlofssonBAlbrektsenTEffects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well beingJ Clin Pharmacol19943477427477929868
   PubMed Web of Science ®Google Scholar